

Press release

Empros Pharma AB (“Empros Pharma” or “Empros”) and Megapharm Ltd. (“Megapharm”) announce today that they have entered into a Letter of Intent (“LOI”) for EMP16, Empros’s product for the treatment of overweight and obesity which is currently under development.

Both parties have declared their mutual intent to enter into a license agreement concerning the commercialization of EMP16 through the signing of a Letter of Intent. Megapharm has both the capacity and expertise to in-license, register, market and distribute EMP16 in Israel. Under the LOI, Empros is willing to assign to Megapharm exclusive distribution rights for EMP16 in the territory.

Arvid Söderhäll, CEO of Empros commented “We are excited to have signed this Letter of Intent with Megapharm and this represents the first publicly announced interest in the commercial potential of EMP16. This is of major importance to Empros and gives us the confidence to continue to expand and accelerate our market development activities towards a future launch”.

Miron Drucker, CEO of Megapharm added “There is a clear need for a first line obesity treatment in Israel and we believe that EMP16 has the potential to fulfil this. We are excited by the prospect of the collaboration and look forward to working with Empros to bring the product to market”.

[Canaccord Genuity](#) is acting as exclusive business development advisor for EMP16 and organizations with an interest to commercialize EMP16 are encouraged to contact Issac Jacob at Canaccord.

About Empros

Empros Pharma develops EMP16, a pharmaceutical treatment against overweight and obesity. Empros Pharma AB was founded in late 2013 by senior researchers and entrepreneurs at Uppsala University together with the external investor Flerie Invest. The EMP16 product has demonstrated its efficacy in a proof-of-concept clinical trial, as recently published in *Obesity: Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: A randomized, placebo-controlled trial* - Holmbäck - 2022 - Obesity - Wiley Online Library.

Empros continues to progress the clinical development of EMP16 in two more clinical trials that will run during 2023. The early phase safety and tolerability trial finalized in 2017 demonstrated a best-in-class safety profile and improved blood glucose control.

About Megapharm

Megapharm Ltd. is one of the leading privately held pharmaceutical companies in Israel, expert in marketing and distribution in the pharmaceutical and healthcare industry. Founded in 1989, Megapharm has more than 33 years successful track record for introducing and commercializing innovative treatments in Israel. Megapharm has established partnerships with numerous international companies, leading to a dynamic growth in sales. Megapharm's core expertise are within: Oncology and Hematology-Oncology, CNS, Orphan and Metabolic drugs. Maintaining long-standing relations with Ministry of Health, Health Funds, hospitals, local medical centers, physicians and KOLs. Operating under strict GMP and ISO standards – ensuring that all procedures and business conducts are of the highest market standards.